TRVI Logo

Trevi Therapeutics, Inc. (TRVI) 

NASDAQ$6.29
Market Cap
$562.11M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
886 of 925
Rank in Industry
504 of 528

TRVI Insider Trading Activity

TRVI Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$000
Sells
$1,119,35115100

Related Transactions

Delfini LisaChief Financial Officer0$01$11,485$-11,485
Meeker David Pdirector0$01$13,353$-13,353
SCIASCIA THOMASChief Scientific Officer0$05$272,220$-272,220
GOOD JENNIFER LPresident & CEO0$07$273,416$-273,416
Simon FarrellChief Commercial Officer0$01$548,878$-548,878

About Trevi Therapeutics, Inc.

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in â€¦

Insider Activity of Trevi Therapeutics, Inc.

Over the last 12 months, insiders at Trevi Therapeutics, Inc. have bought $0 and sold $1.12M worth of Trevi Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Trevi Therapeutics, Inc. have bought $22.8M and sold $388,241 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 2,631,578 shares for transaction amount of $5M was made by NEA 16 GP, LLC () on 2022‑04‑11.

List of Insider Buy and Sell Transactions, Trevi Therapeutics, Inc.

2025-03-10SaleSimon FarrellChief Commercial Officer
81,313
0.1012%
$6.75$548,878+3.79%
2024-09-09SaleGOOD JENNIFER LPresident & CEO
1,840
0.0025%
$3.04$5,587+10.26%
2024-09-06SaleGOOD JENNIFER LPresident & CEO
4,219
0.006%
$3.03$12,784+16.10%
2024-09-05SaleGOOD JENNIFER LPresident & CEO
40,277
0.0557%
$3.11$125,310+10.00%
2024-09-04SaleGOOD JENNIFER LPresident & CEO
10,981
0.0155%
$3.02$33,205+14.92%
2024-09-03SaleGOOD JENNIFER LPresident & CEO
3,863
0.0054%
$3.02$11,677+13.47%
2024-08-27SaleMeeker David Pdirector
4,555
0.0063%
$2.93$13,353+14.78%
2024-08-19SaleSCIASCIA THOMASChief Scientific Officer
16,496
0.0227%
$2.96$48,883+11.11%
2024-08-16SaleSCIASCIA THOMASChief Scientific Officer
18,660
0.0268%
$2.76$51,440+19.13%
2024-08-15SaleSCIASCIA THOMASChief Scientific Officer
12,745
0.0185%
$2.79$35,513+20.00%
2024-08-14SaleSCIASCIA THOMASChief Scientific Officer
100
0.0001%
$2.75$275+26.44%
2024-05-29SaleSCIASCIA THOMASChief Scientific Officer
53,368
0.0761%
$2.55$136,110+22.05%
2024-05-22SaleDelfini LisaChief Financial Officer
4,350
0.0062%
$2.64$11,485+16.23%
2024-05-20SaleGOOD JENNIFER LPresident & CEO
25,037
0.0359%
$2.86$71,576+8.83%
2024-05-10SaleGOOD JENNIFER LPresident & CEO
4,578
0.0069%
$2.90$13,276+11.36%
2023-10-11SaleDelfini LisaChief Financial Officer
785
0.0012%
$2.02$1,586+32.11%
2023-09-11SaleDelfini LisaChief Financial Officer
711
0.0011%
$2.20$1,564+15.27%
2023-08-11SaleDelfini LisaChief Financial Officer
682
0.0011%
$2.36$1,610-1.05%
2023-07-11SaleDelfini LisaChief Financial Officer
687
0.0007%
$2.34$1,608+0.55%
2023-06-12SaleDelfini LisaChief Financial Officer
610
0.0006%
$2.64$1,610-11.72%
Total: 75
*Gray background shows transactions not older than one year

Insider Historical Profitability

<0.0001%
Meeker David Pdirector
352489
0.3944%
$2.22M11<0.0001%
GOOD JENNIFER LPresident & CEO
213313
0.2387%
$1.34M17<0.0001%
BASKETT FOREST
10421428
11.6616%
$65.55M31+1.73%
Makhzoumi Mohamad
10421428
11.6616%
$65.55M31+1.73%
NEA 16 GP, LLC
10421428
11.6616%
$65.55M10<0.0001%
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

$36,510,315
95
8.95%
$600.23M
$587,109,125
90
3.17%
$509.59M
$14,527,743
76
38.40%
$473.67M
Trevi Therapeutics, Inc.
(TRVI)
$678,065,999
37
-13.32%
$562.11M
$94,912,877
34
-7.15%
$605.37M

TRVI Institutional Investors: Active Positions

Increased Positions74+98.67%28M+47.62%
Decreased Positions31-41.33%6M-10.48%
New Positions27New13MNew
Sold Out Positions8Sold Out260,157Sold Out
Total Postitions118+57.33%80M+37.14%

TRVI Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Nea Management Company, Llc$51,394.0012.78%11.37M00%2024-12-31
Frazier Life Sciences Management, L.P.$48,205.0011.98%10.66M+3M+44.49%2024-12-31
Viking Global Investors Lp$19,888.004.94%4.4M00%2024-12-31
Rubric Capital Management Lp$19,007.004.72%4.21M-821,802-16.35%2024-12-31
Point72 Asset Management, L.P.$18,759.004.66%4.15M+4MNew2024-12-31
Blackrock, Inc.$17,757.004.41%3.93M+706,710+21.94%2024-12-31
Vanguard Group Inc$15,862.003.94%3.51M+246,832+7.57%2024-12-31
Vivo Capital, Llc$15,765.003.92%3.49M+2M+116.25%2024-12-31
Woodline Partners Lp$14,521.003.61%3.21M+3M+429.93%2024-12-31
Mpm Bioimpact Llc$13,989.003.48%3.09M+2M+101.16%2024-12-31

Financial Ratios

Summary
Comparison with Competitors

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
1.7SellsBuysStrong BuyBuyHoldSellStrong SellTRVIHighAverageLowSeries 4